What is Integrated Biopharma Inc's earnings per share (EPS)?

Integrated Biopharma Inc (INBP) reported diluted earnings per share of $0.03 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Integrated Biopharma Inc Financials

INBP

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE June

This page shows Integrated Biopharma Inc (INBP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INBP FY2025 2026-05-08

FY2025’s profit rebound came more from margin repair and working-capital release than from a dramatic sales surge.

After hovering near break-even in FY2023-FY2024, FY2025 turned a modest sales recovery into a much larger earnings recovery as revenue rose only 8.0%, showing the improvement came from better economics per sale rather than from volume alone. Gross margin rebuilt while SG&A stayed restrained, lifting operating income from $251K to $2.0M; that points more to improved product-cost or sales mix than to scale by itself.

The business still runs on a thin gross-margin base—just 10.2% in FY2025—so small shifts in sourcing, product mix, or customer allowances can materially change profit. That sensitivity helps explain why revenue looked only modestly different from FY2024 while earnings moved much more sharply, making this a business where execution on costs matters as much as sales growth.

The cash conversion was healthier than headline profit: FY2025 operating cash flow was $2.1M versus net income of $808K, and capex remained light, so most cash generated did not need to be recycled into maintenance spending. Liquidity also strengthened as the current ratio reached 4.4x and inventory dropped to $9.4M, reducing the chance that day-to-day funding pressure overrides operating decisions.

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Integrated Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Integrated Biopharma Inc has an operating margin of 3.7%, meaning the company retains $4 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is up from 0.5% the prior year.

Growth

Integrated Biopharma Inc's revenue grew 8.0% year-over-year to $54.4M, a solid pace of expansion. This earns a growth score of 39/100.

Leverage

Integrated Biopharma Inc carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.42, Integrated Biopharma Inc holds $4.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.

Cash Flow

Integrated Biopharma Inc has a free cash flow margin of 3.5%, earning a moderate score of 31/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Integrated Biopharma Inc generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 16/100. This is up from 0.6% the prior year.

Altman Z-Score Grey Zone

2.12

Integrated Biopharma Inc scores 2.12, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Strong

7/9

Integrated Biopharma Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.56x

For every $1 of reported earnings, Integrated Biopharma Inc generates $2.56 in operating cash flow ($2.1M OCF vs $808K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

43.9x

Integrated Biopharma Inc earns $43.9 in operating income for every $1 of interest expense ($2.0M vs $46K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$54.4M

YoY+8.0%

5Y CAGR+0.6%

10Y CAGR+4.9%

Integrated Biopharma Inc generated $54.4M in revenue in fiscal year 2025. This represents an increase of 8.0% from the prior year.

EBITDA

$2.3M

YoY+319.0%

5Y CAGR-8.1%

10Y CAGR+5.2%

Integrated Biopharma Inc's EBITDA was $2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 319.0% from the prior year.

Net Income

$808K

YoY+621.4%

5Y CAGR-27.8%

10Y CAGR+24.1%

Integrated Biopharma Inc reported $808K in net income in fiscal year 2025. This represents an increase of 621.4% from the prior year.

EPS (Diluted)

$0.03

5Y CAGR-25.4%

Integrated Biopharma Inc earned $0.03 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

$1.9M

YoY+380.5%

5Y CAGR+10.7%

Integrated Biopharma Inc generated $1.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 380.5% from the prior year.

Cash & Debt

$3.6M

YoY+115.6%

5Y CAGR+55.2%

10Y CAGR+52.0%

Integrated Biopharma Inc held $3.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+3.2%

5Y CAGR+0.9%

10Y CAGR+4.0%

Integrated Biopharma Inc had 31M shares outstanding in fiscal year 2025. This represents an increase of 3.2% from the prior year.

Margins & Returns

Gross Margin

10.2%

YoY+2.5pp

5Y CAGR-2.5pp

10Y CAGR-6.1pp

Integrated Biopharma Inc's gross margin was 10.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the prior year.

Operating Margin

3.7%

YoY+3.2pp

5Y CAGR-2.5pp

10Y CAGR+0.4pp

Integrated Biopharma Inc's operating margin was 3.7% in fiscal year 2025, reflecting core business profitability. This is up 3.2 percentage points from the prior year.

Net Margin

1.5%

YoY+1.3pp

5Y CAGR-6.3pp

10Y CAGR+1.2pp

Integrated Biopharma Inc's net profit margin was 1.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.3 percentage points from the prior year.

Return on Equity

4.0%

YoY+3.4pp

5Y CAGR-63.7pp

Integrated Biopharma Inc's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.4 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$191K

YoY-65.5%

5Y CAGR-2.2%

10Y CAGR+20.3%

Integrated Biopharma Inc invested $191K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 65.5% from the prior year.

INBP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$54.4M+8.0%	$50.3M-0.7%	$50.7M-9.9%	$56.2M-11.5%	$63.6M+20.4%	$52.8M
Cost of Revenue	$48.8M+5.1%	$46.4M-0.4%	$46.6M-6.2%	$49.7M-8.1%	$54.1M+17.5%	$46.0M
Gross Profit	$5.6M+43.2%	$3.9M-4.4%	$4.1M-38.0%	$6.6M-30.9%	$9.5M+40.9%	$6.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$3.5M-2.5%	$3.6M-7.8%	$3.9M+3.5%	$3.8M+3.0%	$3.7M+6.6%	$3.5M
Operating Income	$2.0M+704.8%	$251K+109.2%	$120K-95.6%	$2.7M-52.5%	$5.8M+77.5%	$3.3M
Interest Expense	$46K-11.5%	$52K0.0%	$52K-59.4%	$128K-50.0%	$256K-35.5%	$397K
Income Tax	$1.3M+703.8%	$156K+16.4%	$134K+110.8%	-$1.2M-62.0%	-$766K+24.9%	-$1.0M
Net Income	$808K+621.4%	$112K+429.4%	-$34K-100.9%	$3.8M-52.1%	$8.0M+95.1%	$4.1M
EPS (Diluted)	$0.03	$0.00	$0.00-100.0%	$0.12-52.0%	$0.25+92.3%	$0.13

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$10.1M-10.4%	$11.3M-11.1%	$12.7M-10.5%	$14.2M+1.6%	$13.9M+10.6%	$12.6M-7.4%	$13.6M+6.8%	$12.7M
Cost of Revenue	$10.4M-7.7%	$11.3M-3.6%	$11.7M-8.2%	$12.7M+2.5%	$12.4M+8.3%	$11.4M-6.6%	$12.2M+6.8%	$11.5M
Gross Profit	-$276K-1051.7%	$29K-97.2%	$1.0M-30.6%	$1.5M-5.3%	$1.6M+32.5%	$1.2M-14.6%	$1.4M+6.8%	$1.3M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$809K-14.2%	$943K+10.2%	$856K-2.7%	$880K+8.4%	$812K-16.2%	$969K+10.0%	$881K-0.1%	$882K
Operating Income	-$1.1M-18.7%	-$914K-660.7%	$163K-72.3%	$589K-20.3%	$739K+265.8%	$202K-58.8%	$490K+21.9%	$402K
Interest Expense	-$39K+2.5%	-$40K-21.2%	-$33K-143.4%	$76K+1620.0%	-$5K+54.5%	-$11K+21.4%	-$14K-124.1%	$58K
Income Tax	-$198K-76.8%	-$112K-253.4%	$73K-90.6%	$773K+362.9%	$167K+142.0%	$69K-71.8%	$245K+67.8%	$146K
Net Income	-$837K-9.8%	-$762K-719.5%	$123K+169.1%	-$178K-129.1%	$611K+426.7%	$116K-55.2%	$259K-3.4%	$268K
EPS (Diluted)	$-0.030.0%	$-0.03	$0.00	N/A	$0.02+100.0%	$0.010.0%	$0.01	N/A

INBP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$24.9M-5.0%	$26.2M0.0%	$26.2M+3.8%	$25.3M-0.7%	$25.4M+10.9%	$22.9M
Current Assets	$18.8M+5.0%	$17.9M+9.2%	$16.4M-1.5%	$16.6M-7.6%	$18.0M+9.3%	$16.5M
Cash & Equivalents	$3.6M+115.6%	$1.7M+27.4%	$1.3M+297.6%	$331K+57.6%	$210K-47.8%	$402K
Inventory	$9.4M-16.7%	$11.2M+9.6%	$10.3M-7.2%	$11.1M-5.5%	$11.7M0.0%	$11.7M
Accounts Receivable	$5.4M+16.3%	$4.7M+3.5%	$4.5M-7.7%	$4.9M-15.4%	$5.8M+4.9%	$5.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.6M-34.2%	$7.0M+6.1%	$6.6M-1.6%	$6.7M-39.9%	$11.1M-34.2%	$16.9M
Current Liabilities	$4.2M-30.6%	$6.1M+26.8%	$4.8M-8.3%	$5.3M-43.0%	$9.2M-29.5%	$13.1M
Long-Term Debt	N/A	N/A	$7K-86.8%	$53K	$0-100.0%	$1.4M
Total Equity	$20.3M+5.6%	$19.2M+2.0%	$18.9M+1.5%	$18.6M+29.6%	$14.3M+136.3%	$6.1M
Retained Earnings	-$31.4M+2.5%	-$32.2M+0.3%	-$32.3M-0.1%	-$32.3M+10.6%	-$36.1M+18.1%	-$44.2M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$26.7M+13.3%	$23.5M-7.8%	$25.5M+2.6%	$24.9M-2.9%	$25.7M0.0%	$25.7M-2.0%	$26.2M-0.1%	$26.2M
Current Assets	$18.0M+0.9%	$17.8M-9.2%	$19.6M+4.6%	$18.8M+1.2%	$18.5M+2.2%	$18.2M-0.9%	$18.3M+2.4%	$17.9M
Cash & Equivalents	$5.8M+9.6%	$5.3M+12.3%	$4.7M+30.9%	$3.6M+22.1%	$3.0M+20.3%	$2.5M+8.4%	$2.3M+35.4%	$1.7M
Inventory	$8.1M-2.9%	$8.4M-20.1%	$10.5M+11.8%	$9.4M-7.1%	$10.1M-8.9%	$11.1M-1.4%	$11.2M-0.2%	$11.2M
Accounts Receivable	$3.7M+1.8%	$3.6M-9.8%	$4.0M-26.6%	$5.4M+6.9%	$5.1M+20.2%	$4.2M-3.6%	$4.4M-6.1%	$4.7M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.7M+103.5%	$3.8M-25.2%	$5.1M+10.2%	$4.6M-13.1%	$5.3M-79.4%	$25.6M+286.6%	$6.6M-4.8%	$7.0M
Current Liabilities	$5.5M+56.1%	$3.5M-25.7%	$4.8M+12.1%	$4.2M-14.7%	$5.0M-10.7%	$5.6M-7.5%	$6.0M-1.5%	$6.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$19.0M-4.0%	$19.8M-3.5%	$20.5M+0.8%	$20.3M-0.3%	$20.4M+103225.4%	$20K-99.9%	$18.6M-3.6%	$19.2M
Retained Earnings	-$32.9M-2.6%	-$32.1M-2.4%	-$31.3M+0.4%	-$31.4M-0.6%	-$31.2M+1.9%	-$31.9M+0.4%	-$32.0M+0.8%	-$32.2M

INBP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$2.1M+119.0%	$943K-23.5%	$1.2M-69.9%	$4.1M+34.1%	$3.0M+127.8%	$1.3M
Capital Expenditures	$191K-65.5%	$553K+376.7%	$116K-76.1%	$486K+64.7%	$295K+37.9%	$214K
Free Cash Flow	$1.9M+380.5%	$390K-65.1%	$1.1M-69.0%	$3.6M+30.9%	$2.8M+144.9%	$1.1M
Investing Cash Flow	-$205K+62.9%	-$553K-398.2%	-$111K+76.1%	-$465K-133.7%	-$199K-80.9%	-$110K
Financing Cash Flow	$78K+369.0%	-$29K+78.7%	-$136K+96.1%	-$3.5M-15.2%	-$3.0M-133.7%	-$1.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	$517K-16.2%	$617K-52.6%	$1.3M+120.1%	$591K-4.1%	$616K+206.5%	$201K-69.4%	$657K+453.2%	-$186K
Capital Expenditures	$0-100.0%	$24K-86.1%	$173K+1830.0%	-$10K-108.6%	$116K+300.0%	$29K-48.2%	$56K-61.6%	$146K
Free Cash Flow	$517K-12.8%	$593K-47.4%	$1.1M+94.1%	$581K+16.2%	$500K+190.7%	$172K-71.4%	$601K+281.0%	-$332K
Investing Cash Flow	$6K+125.0%	-$24K+86.1%	-$173K-4225.0%	-$4K+96.6%	-$116K-300.0%	-$29K+48.2%	-$56K+61.6%	-$146K
Financing Cash Flow	-$11K0.0%	-$11K0.0%	-$11K-116.4%	$67K	$0-100.0%	$18K+357.1%	-$7K+36.4%	-$11K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INBP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	10.2%+2.5pp	7.7%-0.3pp	8.0%-3.6pp	11.7%-3.3pp	14.9%+2.2pp	12.8%
Operating Margin	3.7%+3.2pp	0.5%+0.3pp	0.2%-4.6pp	4.9%-4.2pp	9.1%+2.9pp	6.2%
Net Margin	1.5%+1.3pp	0.2%+0.3pp	-0.1%-6.9pp	6.8%-5.8pp	12.6%+4.8pp	7.8%
Return on Equity	4.0%+3.4pp	0.6%+0.8pp	-0.2%-20.8pp	20.7%-35.2pp	55.9%-11.8pp	67.7%
Return on Assets	3.2%+2.8pp	0.4%+0.6pp	-0.1%-15.3pp	15.2%-16.3pp	31.5%+13.6pp	17.9%
Current Ratio	4.42+1.5	2.92-0.5	3.39+0.2	3.16+1.2	1.95+0.7	1.26
Debt-to-Equity	0.23-0.1	0.36+0.4	0.000.0	0.000.0	0.00-0.2	0.24
FCF Margin	3.5%+2.7pp	0.8%-1.4pp	2.2%-4.2pp	6.4%+2.1pp	4.3%+2.2pp	2.1%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	-2.7%-3.0pp	0.3%-7.8pp	8.0%-2.3pp	10.4%-0.8pp	11.1%+1.8pp	9.3%-0.8pp	10.1%0.0pp	10.1%
Operating Margin	-10.7%-2.6pp	-8.1%-9.4pp	1.3%-2.9pp	4.2%-1.1pp	5.3%+3.7pp	1.6%-2.0pp	3.6%+0.4pp	3.1%
Net Margin	-8.3%-1.5pp	-6.8%-7.7pp	1.0%+2.2pp	-1.3%-5.6pp	4.4%+3.5pp	0.9%-1.0pp	1.9%-0.2pp	2.1%
Return on Equity	-4.4%-0.6pp	-3.9%-4.5pp	0.6%+1.5pp	-0.9%-3.9pp	3.0%-585.0pp	588.0%+586.6pp	1.4%+0.0pp	1.4%
Return on Assets	-3.1%+0.1pp	-3.2%-3.7pp	0.5%+1.2pp	-0.7%-3.1pp	2.4%+1.9pp	0.4%-0.5pp	1.0%-0.0pp	1.0%
Current Ratio	3.25-1.8	5.03+0.9	4.12-0.3	4.42+0.7	3.72+0.5	3.26+0.2	3.04+0.1	2.92
Debt-to-Equity	0.41+0.2	0.19-0.1	0.25+0.0	0.23-0.0	0.26-1299.5	1299.81+1299.4	0.360.0	0.36
FCF Margin	5.1%-0.1pp	5.3%-3.6pp	8.9%+4.8pp	4.1%+0.5pp	3.6%+2.2pp	1.4%-3.0pp	4.4%+7.0pp	-2.6%

Similar Companies

Else Nutrition H BABYF

$1.1M

Bab Inc BABB

$6.6M

Nepra Foods NPRFF

$56.2M

PRECISION PEPTID PNGAF

$15.9M

Steakholder Food MTTCF

$6.7M

Frequently Asked Questions

What is Integrated Biopharma Inc's annual revenue?

Integrated Biopharma Inc (INBP) reported $54.4M in total revenue for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Integrated Biopharma Inc's revenue growing?

Integrated Biopharma Inc (INBP) revenue grew by 8% year-over-year, from $50.3M to $54.4M in fiscal year 2025.

Is Integrated Biopharma Inc profitable?

Yes, Integrated Biopharma Inc (INBP) reported a net income of $808K in fiscal year 2025, with a net profit margin of 1.5%.

What is Integrated Biopharma Inc's EBITDA?

Integrated Biopharma Inc (INBP) had EBITDA of $2.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Integrated Biopharma Inc's gross margin?

Integrated Biopharma Inc (INBP) had a gross margin of 10.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Integrated Biopharma Inc's operating margin?

Integrated Biopharma Inc (INBP) had an operating margin of 3.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Integrated Biopharma Inc's net profit margin?

Integrated Biopharma Inc (INBP) had a net profit margin of 1.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Integrated Biopharma Inc's return on equity (ROE)?

Integrated Biopharma Inc (INBP) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Integrated Biopharma Inc's free cash flow?

Integrated Biopharma Inc (INBP) generated $1.9M in free cash flow during fiscal year 2025. This represents a 380.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Integrated Biopharma Inc's operating cash flow?

Integrated Biopharma Inc (INBP) generated $2.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Integrated Biopharma Inc's total assets?

Integrated Biopharma Inc (INBP) had $24.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Integrated Biopharma Inc's capital expenditures?

Integrated Biopharma Inc (INBP) invested $191K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Integrated Biopharma Inc have outstanding?

Integrated Biopharma Inc (INBP) had 31M shares outstanding as of fiscal year 2025.

What is Integrated Biopharma Inc's current ratio?

Integrated Biopharma Inc (INBP) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.

What is Integrated Biopharma Inc's debt-to-equity ratio?

Integrated Biopharma Inc (INBP) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Integrated Biopharma Inc's return on assets (ROA)?

Integrated Biopharma Inc (INBP) had a return on assets of 3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Integrated Biopharma Inc's Altman Z-Score?

Integrated Biopharma Inc (INBP) has an Altman Z-Score of 2.12, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Integrated Biopharma Inc's Piotroski F-Score?

Integrated Biopharma Inc (INBP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Integrated Biopharma Inc's earnings high quality?

Integrated Biopharma Inc (INBP) has an earnings quality ratio of 2.56x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Integrated Biopharma Inc cover its interest payments?

Integrated Biopharma Inc (INBP) has an interest coverage ratio of 43.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Integrated Biopharma Inc?

Integrated Biopharma Inc (INBP) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.